Cryoport Reports Third Quarter 2026 Financial Results

Cryoport's Q3 2026 revenue rose 14% year over year to $50.2 million, while commercial cell and gene therapy revenue increased 20%; adjusted EBITDA from continuing operations improved to $1.1 million from a $0.6 million loss a year earlier. The company raised full-year 2026 revenue guidance to $197 million–$199 million and reported support for 23 commercial therapies and a record 788 clinical trials. Results were mixed below the revenue line: Q3 net loss widened to $10.9 million from $6.9 million, and gross margin fell to 47.5% from 48.2%.

Analysis

The raise is constructive for demand visibility, but not yet proof of a durable earnings inflection. The updated full-year range implies Q4 revenue of roughly $50–52M—around Q3’s level—so the guidance change supports execution more than a sharp near-term acceleration. More important, service gross margin improved while product gross margin fell; with products still a substantial revenue stream, mix and product cost control may constrain consolidated operating leverage. Adjusted EBITDA of $1.1M is thin relative to the continuing-operations loss, and the reconciliation includes sizeable non-cash/market-sensitive adjustments. Treat “pathway to profitability” as unconfirmed until GAAP losses and cash conversion improve.

The 788-trial base is a pipeline indicator, not contracted future revenue: conversion to commercial logistics depends on trial success, approvals, launch timing and patient uptake. Phase 3 growth and broader labels for CASGEVY could create later volume, but neither guarantees Cryoport revenue near term. The current classification of nearly $186M of convertible notes as current warrants checking maturity, conversion and refinancing terms against the $393M cash-and-investments balance; liquidity is meaningful, but not equivalent to unrestricted excess capital. Near-term catalyst is the earnings call and Q4 execution; over 6–18 months, utilization of new capacity and commercial therapy uptake determine whether fixed-cost leverage appears. Contrarian read: the growth headline may be overvalued as a profitability signal; the revenue trajectory looks steadier than accelerating.

Key Decisions for Investors

• CYRX: Do not chase the headline; consider a small, staged long only on post-call weakness if management confirms Q4 guidance and gives measurable evidence of service-center utilization or improving cash operating performance. Reassess if Q4 revenue falls short of the implied $50–52M range, service growth decelerates materially, or service gross margin reverses.
• Before adding CYRX, verify the convertible-note maturity/conversion provisions, unrestricted liquidity and cash burn in the 10-Q. A near-term funding or dilution concern would outweigh the modest adjusted-EBITDA milestone.
• CRSP and VRTX: Treat the label expansion as a possible multi-quarter treatment-volume tailwind, not an immediate earnings read-through for either company or Cryoport. Monitor treated-patient starts and manufacturing capacity before positioning on this supply-chain link.
• REPL: The approval is a potential customer-volume catalyst, but do not infer material Cryoport revenue from approval alone. Watch launch pace, access/reimbursement and company disclosures on commercial uptake; absent evidence, no separate trade.